TMDX · XBRL financial data

TransMedics Group financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TMDX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	26	30	93	242	442	605
Revenue from contracts with customers	28	31	—	—	—	—
Cost of revenue	9	9	28	88	179	243
Gross profit	17	21	65	154	262	363
Research and development	19	22	27	36	56	69
Selling, general and administrative	24	38	70	120	169	185
Total operating expenses	43	61	97	183	225	254
Operating income (loss)	(26)	(39)	(31)	(29)	37	109
Interest expense	4	4	4	11	14	14
Other income (expense)	2	(1)	(1)	13	—	—
Income tax expense (benefit)	0	—	0	(2)	0	(83)
Net income (loss)	(29)	(44)	(36)	(25)	35	190
Earnings per share, basic USD per share	(1.16)	(1.60)	(1.23)	(0.77)	1.07	5.60
Earnings per share, diluted USD per share	(1.16)	(1.60)	(1.23)	(0.77)	1.01	4.87
Weighted average shares, basic millions of shares	25	28	30	33	33	34
Weighted average shares, diluted millions of shares	25	28	30	33	35	41

Fiscal years (TMDX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	25	26	201	395	337	489
Marketable securities	101	67	—	—	—	—
Accounts receivable	7	6	28	64	98	84
Inventory	12	15	21	44	47	49
Prepaid and other current assets	2	5	3	8	16	16
Total current assets	147	119	252	511	497	638
Property and equipment, net	5	10	19	174	286	328
Right-of-use asset	—	6	5	7	6	5
Goodwill	—	—	—	12	12	12
Total assets	152	135	277	706	804	1,068
Accounts payable	1	7	3	13	10	10
Current portion of long-term debt	—	—	—	—	—	10
Total current liabilities	12	23	24	55	60	89
Long-term debt	35	35	59	—	—	—
Lease liability, non-current	—	9	7	8	6	4
Total liabilities	48	67	90	569	575	595
Accumulated deficit	(398)	(442)	(479)	(504)	(468)	(278)
Total stockholders' equity	104	68	187	137	229	473
Total liabilities and equity	152	135	277	706	804	1,068
Common shares outstanding (cover page) millions of shares	27	28	32	33	34	34

Fiscal years (TMDX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(29)	(44)	(36)	(25)	35	190
Stock-based compensation	2	7	10	20	33	37
Depreciation and amortization	2	2	3	8	20	27
Net cash from operating activities	(30)	(29)	(46)	(13)	49	193
Purchases of property and equipment	0	4	12	152	130	59
Net cash from investing activities	(42)	29	55	(194)	(129)	(59)
Proceeds from long-term debt	—	—	59	—	—	—
Repayments of long-term debt	—	—	36	—	—	—
Net cash from financing activities	76	1	168	400	23	17
Net change in cash	4	1	176	194	(58)	152

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
TransMedics Group	493	203	not reported	34.7M	—	Q3 FY26 10-QSep 30, 2026
Integer Holdings	14	450	37*	34.0M	—	Q3 FY26 10-QOct 2, 2026
iRhythm Holdings	247	224	51*	33.0M	—	Q2 FY26 10-QJun 30, 2026
Masimo	125	404	45	52.4M	—	Q1 FY26 10-QApr 4, 2026
Inspire Medical Systems	191	207	46*	29.0M	—	Q3 FY26 10-QSep 30, 2026
Merit Medical Systems	504	416	65*	59.9M	—	Q3 FY26 10-QSep 30, 2026
GLAUKOS	162	211	39*	59.2M	—	Q3 FY26 10-QSep 30, 2026
Icu Medical	298	552	80*	25.0M	—	Q2 FY26 10-QJun 30, 2026
PROCEPT BioRobotics	218	98	(9)*	57.5M	9.0 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.